bioRxiv preprint doi: https://doi.org/10.1101/2023.02.10.528025; this version posted February 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Positing changes in neutralizing antibody activity for SARS-CoV-2 XBB.1.5 using *in silico* protein modeling

Colby T. Ford[1,2,✉], **Shirish Yasa**[3], **Denis Jacob Machado**[3,4], **Richard Allen White III**[3,4,5], **and Daniel Janies**[3,4]

[1]Tuple, LLC, Charlotte, NC, USA
[2]School of Data Science, University of North Carolina at Charlotte, Charlotte, NC, USA
[3]Dept. of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA
[4]Center for Computational Intelligence to Predict Health ad Environmental Risks (CIPHER), University of North Carolina at Charlotte, Charlotte, NC, USA
[5]North Carolina Research Campus (NCRC), University of North Carolina at Charlotte, Kannapolis, NC

The SARS-CoV-2 variant XBB.1.5 is of concern as it has high transmissibility. XBB.1.5 currently accounts for upwards of 30% of new infections in the United States. One year after our group published the predicted structure of the Omicron (B.1.1.529) variant's receptor binding domain and antibody binding affinity, we return to investigate the new mutations seen in XBB.1.5. Using *in silico* modeling approaches against newer neutralizing antibodies that are shown effective against B.1.1.529, we posit the immune consequences of XBB.1.5's mutations and show that there is no statistically significant difference in overall antibody evasion when comparing to the B.1.1.529, BJ.1, and BM.1.1.1 variants. However, specific noticeable hints of neutralizing activity changes were seen due to particular amino acid changes of interest in the newer variants.

SARS-CoV-2 | Bioinformatics | Structure Prediction | Antibody Docking | SARS-CoV-2 variation

Correspondence: *colby.ford@uncc.edu* or *colby@tuple.xyz*

Introduction

In late November 2022, the United States Centers for Diseases Control stated that they began tracking a new SARS-CoV-2 variant known as XBB. At that time, XBB was responsible for around 3% of all infections. Since then, it has grown to represent 30% of all infections by January 2023 (1, 2).

XBB.1.5 is characterized by 40 mutations in the Spike protein, 22 of which are in the receptor binding domain (RBD) (3). The highly prevalent mutations in the RBD are shown in Table 1 below.

Mutation	Sequences	Prevalence
G339H	10,000	98.35%
R346T	9,992	98.27%
L368I	9,839	96.76%
S371F	9,857	96.94%
S373P	9,856	96.93%
S375F	9,860	96.97%
T376A	9,852	96.89%
D405N	9,895	97.32%
R408S	9,616	94.57%
K417N	9,329	91.75%
N440K	9,687	95.27%
V445P	9,653	94.94%
G446S	9,673	95.13%
N460K	9,757	95.96%
S477N	9,984	98.19%
T478K	9,960	97.95%
E484A	9,943	97.79%
F486P	9,919	97.55%
F490S	9,927	97.63%
Q498R	9,970	98.05%
N501Y	9,983	98.18%
Y505H	9,969	98.04%

Table 1. Prevalence of mutations in receptor binding domain of XBB.1.5. Prevalence is calculated as the percentage of samples (out of 10,168 from GISAID) that contain that mutation. Positions are numbered to their location in the larger Spike protein.

A common concern is that XBB.1.5 may evade existing antibodies from therapy, vaccination, and or previous Omicron (B.1.1.529) infection. It has been proposed that XBB.1.5 is a recombinant strain of the virus from BJ.1 and BM.1.1.1 as portions of the mutated Spike protein appear to be from each parent strain (4, 5). However, alternative hypotheses such as convergent evolution may also explain this similarity of portions of XBB.1.5's mutations to those seen in other variants.

In our previous work on the prediction of the receptor binding domain (RBD) structure of the Omicron variant, our process provided robust predictions, having a root mean square deviation of atomic positions (RMSD) of 0.574Å between the predicted and empirically derived Omicron RBD structures (6). Furthermore, our previous study proved useful as a predictive gauge of antibody efficacy prior to when empirical validations of the Omicron-antibody binding changes could be performed.

In this study, we use the methodology in our previous work to investigate XBB.1.5 and related variants and expand our antibodies of interest to include more recently developed anti-Omicron antibodies.

PREPRINT

bioRxiv preprint doi: https://doi.org/10.1101/2023.02.10.528025; this version posted February 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Results

Across the 4 SARS-CoV-2 variants and 10 antibodies, 40 *in silico* docking experiments were performed. As shown in Figure 1, the mean performance of the included neutralizing antibodies is similar across the four variants, with XBB.1.5 binding being congruent to that of B.1.1.529. Furthermore, across the ten antibodies tested, the binding affinities seen in XBB.1.5 are not categorically worse than B.1.1.529, nor are their differences statistically significant.

When assessing overall antibody performance against BJ.1, we see weakened van der Waals energies as compared to the other three variants. This is depicted in the Uniform Manifold Approximation and Projection (UMAP) in Figure 2 where some antibody locations on the BJ.1 UMAP are increased (decreased binding affinity). However, desolvation energies and the buried surface areas are slightly improved overall.



Fig. 1. Boxplots of antibody binding performance by SARS-CoV-2 variant. Wilcoxon *p*-values are shown to assess the statistical significance of the differences between overall variant-antibody performance.

While there are instances of overall antibody performance increasing or decreasing in pairwise comparisons, we do not see an overarching pattern that would indicate that XBB.1.5 has evolved antibody evasion over B.1.1.529 (or BJ.1 and BM.1.1.1). In other words, XBB.1.5 does not appear to have evolved past current antibody defenses, specifically concerning the ten antibody structures tested in this study.



Fig. 2. UMAP scatter plot of antibody binding affinity metrics, shown by variant. Note that a higher UMAP value is likely indicative of worse performance.

Structural Changes in Neutralization. Of the ten antibodies tested in this study, we will focus on the structural bases in which the antibodies LY-CoV555, LY-CoV1404, and AZD8895 work. The neutralization mechanisms of three antibodies have been extensively studied and have been available as therapeutics for treatment against COVID-19 infections (either currently or previously under the United States Emergency Use Authorization) (7–9).

Bamlanivimab (LY-CoV555). As shown in Figure 3, we see a consistent interaction between Bamlanivimab (LY-CoV555) and the variant RBDs at R/Q493. This differs from Jones et al. (10), which states that F490 and S494 in the RBD are the interfacing residues in this region.



Fig. 3. Interfacing residues of interest from the LY-CoV555 antibody (in light pink) against the four RBD structures.

The PyMOL structural visualizations of the potential interaction residues coincides with the overall metrics returned from

bioRxiv preprint doi: https://doi.org/10.1101/2023.02.10.528025; this version posted February 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

the HADDOCK analyses shown in Table 2. LY-CoV555 shows the worst overall performance against BJ.1 while the performance against B.1.1.529, BM.1.1.1, and XBB.1.5 are quite similar. Though not shown in Figure 3, the latter three complexes show a higher number of interfacing residues overall than in BJ.1, thus supporting the reported affinity metrics.

Metric	B.1.1.529	BJ.1	BM.1.1.1	XBB.1.5
HADDOCK score	-105.1	-70.5	-105.3	-93.4
Van der Waals energy	-87.8	-65.1	-95.3	-87.3
Electrostatic energy	-237.1	-184.9	-148.7	-168.2
Desolvation energy	-12	-17.1	-18.7	-13
Buried Surface Area	2498.1	2155.5	2462.9	2386

Table 2. HADDOCK docking metrics for the LY-CoV555 antibody against the four RBD variants.

Bebtelovimab (LY-CoV1404). Westendorf et al. (11) demonstrated that Bebtelovimab (LY-CoV1404) neutralization activity may be affected by RBD mutations at E484, F490, Q493. Shown in Figure 4, we see interactions from this antibody across all four variants around most of these positions in spite of mutations.



Fig. 4. Interfacing residues of interest from the LY-CoV1404 antibody (in light purple) against the four RBD structures.

These findings for LY-CoV1404 are congruent with the reported affinity metrics from the HADDOCK analyses shown in Table 3. Overall HADDOCK scores are stable across the four variant complexes, though LY-CoV1494 is predicted to have the weakest interaction with XBB.1.5, though marginally, compared to the other three.

Metric	B.1.1.529	BJ.1	BM.1.1.1	XBB.1.5
HADDOCK score	-124	-115.4	-110.9	-109.1
Van der Waals energy	-78.6	-63.9	-75.8	-74
Electrostatic energy	-262.1	-337.7	-290.7	-291.8
Desolvation energy	-30.5	-23	-2.7	-4.5
Buried Surface Area	2457.2	2365.5	2467.1	2454.9

Table 3. HADDOCK docking metrics for the LY-CoV1404 antibody against the four RBD variants.

Tixagevimab (AZD8895). As reported in Dong et al. (12), tixagevimab (AZD8895) there is a critical contact residue at F486 on the RBD. We see this residue being interfaced in B.1.1.529, BJ.1, and BM.1.1.1. However, this residue is mutated to proline at this position in XBB.1.5, though interactions from the antibody to the surrounding RBD residues at G485, P486, and N487 of the RBD still occur. See Figure 5.



Fig. 5. Interfacing residues of interest from the AZD8895 antibody (in bright green) against the four RBD structures.

From the resulting HADDOCK metrics shown in Table 4, it would appear that this F486P mutation may increase the binding affinity with the AZD8895, especially in terms of van der Waals and electrostatic energies. Interfacing residues are abundant across all four of these AZD8895-RBD complexes (in addition to those shown in Figure 5), thus providing additional agreement to the strong affinity metrics reported by HADDOCK.

Metric	B.1.1.529	BJ.1	BM.1.1.1	XBB.1.5
HADDOCK score	-93.5	-88	-84.8	-123.8
Van der Waals energy	-71.5	-64.3	-86.7	-90.7
Electrostatic energy	-230	-215.5	-150	-256.3
Desolvation energy	-4.5	-8.4	-8.9	-5.5
Buried Surface Area	2259.5	2134.6	2482	2470.8

Table 4. HADDOCK docking metrics for the AZD8895 antibody against the four RBD variants.

bioRxiv preprint doi: https://doi.org/10.1101/2023.02.10.528025; this version posted February 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Methods

The *in silico* modeling approach taken includes the curation or generation of the RBD structures for four SARS-CoV-2 variants and ten neutralizing antibody structures. Then, each antibody structure was docked against each RBD structure and binding affinity metrics were collected for comparison.

RBD Structures. The Spike protein structure of the SARS-CoV-2 Omicron variant (B.1.1.529) was obtained from Protein Data Bank (PDB: 7t9j) (13). This structure was then trimmed to the RBD residues 339-528.

RBD sequences for BJ.1, BM.1.1.1, and XBB.1.5 were derived from representative samples found on GISAID:

BJ.1: `EPI_ISL_16182897`
BM.1.1: `EPI_ISL_15658180`
XBB.1.5: `EPI_ISL_16505393`

The RBD structures of BJ.1, BM.1.1.1, and XBB.1.5 were then predicted with these sequences using AlphaFold2 (ColabFold-mmseqs2 version) (14, 15). Then, the most confident structure of each was used in subsequent docking analyses.

Antibody Structures. Representative antibody structures were collected from various Protein Data Bank entries ranging from antibodies derived from infected patients (or patients with "breakthrough" infections) or commercially available antibodies used in the treatment of COVID-19. See Table 5.

Only a fragment antigen-binding (Fab) region of the antibodies was used in the subsequent docking analyses.

Antibody	Other Names	PDB ID	Citation
LY-CoV555	bamlanivimab, LY3819253	7kmg	Jones et al.
LY-CoV1404	bebtelovimab, LY3853113	7mmo	Westendorf et al.
AZD1061	cilgavimab	7l7e	Dong et al.
AZD8895	tixagevimab	7l7e	Dong et al.
58G6		7e3l	Li et al.
CV38-142		7lm9	Liu et al.
C110		7k8p	Barnes et al.
P5C3		7qtj	Fenwick et al.
EY6A		7zf3	Nutalai et al.
COVOX-150		7zf8	Nutalai et al.

Table 5. List of antibodies and their source PDB IDs used in this work.

Docking. To prepare the Fab structures, we renumbered residues according to HADDOCK's requirements such that there are no overlapping residue IDs between the heavy and light chains of the Fab's .PDB file. Residues in the Fab structures' complementarity-determining regions (CDRs) were selected as "active residues" for the docking analyses.

Residues in the S1 position of the RBD were selected as the "active residues" of the RBD structures. Since all of the input RBD .PDB files were renumbered to numbers 339-528, all of the input RBD files share the same "active residue" numbers.

Each of the ten antibody structures where docked against each of the four RBD structures using HADDOCK v2.4, a biomolecular modeling software that provides docking predictions for provided structures (24).

The HADDOCK system outputs multiple metrics for the predicted binding affinities and an output set of .PDB files containing the antibody docked against the RBD protein.

This process resulted in forty sets of docked structures. Each set contains many antibody-RBD complex conformations, from which we selected the top-performing structure for each antibody-RBD pair. We used this top-performing complex for subsequent structural investigations into interfacing residues and docking positions.

These analyses were performed on the antibody-RBD structure pairs shown in Figure 1. The multiple metrics were used to assess the overall binding affinity changes between SARS-CoV-2 variants across multiple representative antibodies.

Further, the docked Protein Data bank Files (PDB) were manually reviewed using PyMol to search for interfacing residues between the RBD and Fab structures that may indicate neutralizing activity.

Conclusions

Building on our previous work (6) in studying Omicron's structure, we have continued to demonstrate the utility of *in silico* modeling for predicting whether antibody neutralization changes with the evolution of new SARS-CoV-2 variants. Given that empirical structural validation of antibody binding is costly and takes an extended time, *in silico* pipelines, as illustrated here, provide a faster method at near or at empirical resolution. Such modeling illuminates insights into the potential severity of a new variant and provides predictions on antibody neutralization. These predictions inform public health considerations and provide a blueprint of rational drug design as expected therapeutic and vaccine (and booster) efficacy. It also suggests downstream effects of the loss of efficacy, such as breakthrough infection and associated healthcare burden.

The climb in cases of COVID disease linked to XBB.1.5 indicates that XBB.1.5 could be a very serious subvariant of Omicron. While other studies are needed to assess transmissibility, virulence, pathogenicity, and other facets of viral severity and epidemiology, this study predicts that many current therapeutic and infection-derived antibodies provide neutralization abilities similar to B.1.1.529 for XBB.1.5.

The increased binding affinity of XBB.1.5 for ACE2 may lead to increased transmissibility at the population level. The results here do not indicate that we can expect increased disease severity on an individual level for patients that avail themselves of therapeutics and vaccination.

Supplementary Materials

All code, data, results, and protein structure files can be found on GitHub at https://github.com/colbyford/SARS-CoV-2_XBB.1.5_Spike-RBD_Predictions.

ACKNOWLEDGEMENTS

We acknowledge the following entities at the University of North Carolina at Charlotte: The Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER), North Carolina Research Center at Kannapolis, The Department of Bioinformatics and Genomics, The College of Computing and Informatics, and the University Research Computing group.

PREPRINT

bioRxiv preprint doi: https://doi.org/10.1101/2023.02.10.528025; this version posted February 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

For the GISAID sequences EPI_ISL_16505393, EPI_ISL_16182897, and EPI_ISL_15658180, we thank the UNC Charlotte Environmental Monitoring Laboratory, the National Institute of Biomedical Genomics in India, and the British Columbia Centre for Disease Control Public Health Laboratory in Vancouver, Canada, respectively.

Bibliography

1. Ewen Callaway. Coronavirus variant XBB.1.5 rises in the united states - is it a global threat? *Nature*, 613(7943):222–223, January 2023.
2. E Callaway. Is coronavirus variant XBB.1.5 a global threat? *Nature*, 613:222–223, 1 2023. doi: 10.1038/d41586-023-00014-3.
3. Outbreak.info SARS-COV-2 data explorer - XBB.1.5, 2023. https://outbreak.info/compare-lineages?pango=XBB.1.5&gene=S&threshold=75&nthresh=1&sub=false&dark=false.
4. Rajesh Karyakarte, Rashmita Das, Sonali Dudhate, Jeanne Agarasen, Praveena Pillai, Priyanka Chandankhede, Rutika Labshetwar, Yogita Gadiyal, Mansi Rajmane, Preeti Kulkarni, et al. Clinical characteristics and outcomes of laboratory-confirmed SARS-CoV-2 cases infected with Omicron subvariants and XBB recombinant variant. *MedRxiv*, pages 2023–01, 2023. doi: 10.1101/2023.01.05.23284211.
5. Ninaad Lasrado, Ai-ris Collier, Jessica Miller, Nicole Hachmann, Jinyan Liu, Michaela Sciacca, Cindy Wu, Trisha Anand, Esther Bondzie, Jana Fisher, et al. Waning immunity against XBB.1.5 following bivalent mrna boosters. *bioRxiv*, pages 2023–01, 2023. doi: 10.1101/2023.01.22.525079.
6. Colby T. Ford, Denis Jacob Machado, and Daniel A. Janies. Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions. *Frontiers in Virology*, 2, 2022. ISSN 2673-818X. doi: 10.3389/fviro.2022.830202.
7. US Food and Drug Administration. Emergency use authorization 094, 2022. https://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf.
8. US Food and Drug Administration. Emergency use authorization 111, 2022. https://www.fda.gov/media/156151/download.
9. US Food and Drug Administration. Emergency use authorization 104, 2023. https://www.fda.gov/media/154704/download.
10. Bryan E. Jones, Patricia L. Brown-Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, Julian Davies, Thomas P. Cujec, Christopher M. Wiethoff, Jamie L. Blackbourne, Beverly A. Heinz, Denisa Foster, Richard E. Higgs, Deepa Balasubramaniam, Lingshu Wang, Yi Zhang, Eun Sung Yang, Roza Bidshahri, Lucas Kraft, Yuri Hwang, Stefanie Žentelis, Kevin R. Jepson, Rodrigo Goya, Maia A. Smith, David W. Collins, Samuel J. Hinshaw, Sean A. Tycho, Davide Pellacani, Ping Xiang, Krithika Muthuraman, Solmaz Sobhanifar, Marissa H. Piper, Franz J. Triana, Jorg Hendle, Anna Pustilnik, Andrew C. Adams, Shawn J. Berens, Ralph S. Baric, David R. Martinez, Robert W. Cross, Thomas W. Geisbert, Viktoriya Borisevich, Olubukola Abiona, Hayley M. Belli, Maren de Vries, Adil Mohamed, Meike Dittmann, Marie I. Samanovic, Mark J. Mulligan, Jory A. Goldsmith, Ching-Lin Hsieh, Nicole V. Johnson, Daniel Wrapp, Jason S. McLellan, Bryan C. Barnhart, Barney S. Graham, John R. Mascola, Carl L. Hansen, and Ester Falconer. The neutralizing antibody, ly-cov555, protects against sars-cov-2 infection in nonhuman primates. *Science Translational Medicine*, 13(593):eabf1906, 2021. doi: 10.1126/scitranslmed.abf1906.
11. Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, Denisa Foster, Peter Vaillancourt, Matthew Wiggin, Erica Lovett, Robin van der Lee, Jörg Hendle, Anna Pustilnik, J. Michael Sauder, Lucas Kraft, Yuri Hwang, Robert W. Siegel, Jinbiao Chen, Beverly A. Heinz, Richard E. Higgs, Nicole L. Kallewaard, Kevin Jepson, Rodrigo Goya, Maia A. Smith, David W. Collins, Davide Pellacani, Ping Xiang, Valentine de Puyraimond, Marketa Ricicova, Lindsay Devorkin, Caitlin Pritchard, Aoise O'Neill, Kush Dalal, Pankaj Panwar, Harveer Dhupar, Fabian A. Garces, Courtney A. Cohen, John M. Dye, Kathleen E. Huie, Catherine V. Badger, Darwyn Kobasa, Jonathan Audet, Joshua J. Freitas, Saleema Hassanali, Ina Hughes, Luis Munoz, Holly C. Palma, Bharathi Ramamurthy, Robert W. Cross, Thomas W. Geisbert, Vineet Menachery, Kumari Lokugamage, Viktoriya Borisevich, Iliana Lanz, Lisa Anderson, Payal Sipahimalani, Kizzmekia S. Corbett, Eun Sung Yang, Yi Zhang, Wei Shi, Tongqing Zhou, Misook Choe, John Misasi, Peter D. Kwong, Nancy J. Sullivan, Barney S. Graham, Tara L. Fernandez, Carl L. Hansen, Ester Falconer, John R. Mascola, Bryan E. Jones, and Bryan C. Barnhart. Ly-cov1404 (bebtelovimab) potently neutralizes sars-cov-2 variants. *Cell Reports*, 39(7):110812, 2022. ISSN 2211-1247. doi: https://doi.org/10.1016/j.celrep.2022.110812.
12. Jinhui Dong, Seth J. Zost, Allison J. Greaney, Tyler N. Starr, Adam S. Dingens, Elaine C. Chen, Rita E. Chen, James Brett Case, Rachel E. Sutton, Pavlo Gilchuk, Jessica Rodriguez, Erica Armstrong, Christopher Gainza, Rachel S. Nargi, Elad Binshtein, Xuping Xie, Xianwen Zhang, Pei-Yong Shi, James Logue, Stuart Weston, Marisa E. McGrath, Matthew B. Frieman, Tyler Brady, Kevin M. Tuffy, Helen Bright, Yueh-Ming Loo, Patrick M. McTamney, Mark T. Esser, Robert H. Carnahan, Michael S. Diamond, Jesse D. Bloom, and James E. Crowe. Genetic and structural basis for sars-cov-2 variant neutralization by a two-antibody cocktail. *Nature Microbiology*, 6(10):1233–1244, Oct 2021. ISSN 2058-5276. doi: 10.1038/s41564-021-00972-2.
13. Dhiraj Mannar, James W. Saville, Xing Zhu, Shanti S. Srivastava, Alison M. Berezuk, Katharine S. Tuttle, Ana Citlali Marquez, Inna Sekirov, and Sriram Subramaniam. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. *Science*, 375(6582):760–764, 2022. doi: 10.1126/science.abn7760.
14. John Jumper, Richard Evans, Alexander Pritzel, Tim Green, Michael Figurnov, Olaf Ronneberger, Kathryn Tunyasuvunakool, Russ Bates, Augustin Žídek, Anna Potapenko, Alex Bridgland, Clemens Meyer, Simon A. A. Kohl, Andrew J. Ballard, Andrew Cowie, Bernardino Romera-Paredes, Stanislav Nikolov, Rishub Jain, Jonas Adler, Trevor Back, Stig Petersen, David Reiman, Ellen Clancy, Michal Zielinski, Martin Steinegger, Michalina Pacholska, Tamas Berghammer, Sebastian Bodenstein, David Silver, Oriol Vinyals, Andrew W. Senior, Koray Kavukcuoglu, Pushmeet Kohli, and Demis Hassabis. Highly accurate protein structure prediction with AlphaFold. *Nature*, 596(7873):583–589, Aug 2021. ISSN 1476-4687. doi: 10.1038/s41586-021-03819-2.
15. Milot Mirdita, Konstantin Schütze, Yoshitaka Moriwaki, Lim Heo, Sergey Ovchinnikov, and Martin Steinegger. ColabFold: making protein folding accessible to all. *Nature Methods*, 19 (6):679–682, Jun 2022. ISSN 1548-7105. doi: 10.1038/s41592-022-01488-1.
16. Bryan E. Jones, Patricia L. Brown-Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, Julian Davies, Thomas P. Cujec, Christopher M. Wiethoff, Jamie L. Blackbourne, Beverly A. Heinz, Denisa Foster, Richard E. Higgs, Deepa Balasubramaniam, Lingshu Wang, Yi Zhang, Eun Sung Yang, Roza Bidshahri, Lucas Kraft, Yuri Hwang, Stefanie Žentelis, Kevin R. Jepson, Rodrigo Goya, Maia A. Smith, David W. Collins, Samuel J. Hinshaw, Sean A. Tycho, Davide Pellacani, Ping Xiang, Krithika Muthuraman, Solmaz Sobhanifar, Marissa H. Piper, Franz J. Triana, Jorg Hendle, Anna Pustilnik, Andrew C. Adams, Shawn J. Berens, Ralph S. Baric, David R. Martinez, Robert W. Cross, Thomas W. Geisbert, Viktoriya Borisevich, Olubukola Abiona, Hayley M. Belli, Maren de Vries, Adil Mohamed, Meike Dittmann, Marie I. Samanovic, Mark J. Mulligan, Jory A. Goldsmith, Ching-Lin Hsieh, Nicole V. Johnson, Daniel Wrapp, Jason S. McLellan, Bryan C. Barnhart, Barney S. Graham, John R. Mascola, Carl L. Hansen, and Ester Falconer. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Science Translational Medicine*, 13(593):eabf1906, 2021. doi: 10.1126/scitranslmed.abf1906.
17. Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, Denisa Foster, Peter Vaillancourt, Matthew Wiggin, Erica Lovett, Robin van der Lee, Jörg Hendle, Anna Pustilnik, J. Michael Sauder, Lucas Kraft, Yuri Hwang, Robert W. Siegel, Jinbiao Chen, Beverly A. Heinz, Richard E. Higgs, Nicole L. Kallewaard, Kevin Jepson, Rodrigo Goya, Maia A. Smith, David W. Collins, Davide Pellacani, Ping Xiang, Valentine de Puyraimond, Marketa Ricicova, Lindsay Devorkin, Caitlin Pritchard, Aoise O'Neill, Kush Dalal, Pankaj Panwar, Harveer Dhupar, Fabian A. Garces, Courtney A. Cohen, John M. Dye, Kathleen E. Huie, Catherine V. Badger, Darwyn Kobasa, Jonathan Audet, Joshua J. Freitas, Saleema Hassanali, Ina Hughes, Luis Munoz, Holly C. Palma, Bharathi Ramamurthy, Robert W. Cross, Thomas W. Geisbert, Vineet Menachery, Kumari Lokugamage, Viktoriya Borisevich, Iliana Lanz, Lisa Anderson, Payal Sipahimalani, Kizzmekia S. Corbett, Eun Sung Yang, Yi Zhang, Wei Shi, Tongqing Zhou, Misook Choe, John Misasi, Peter D. Kwong, Nancy J. Sullivan, Barney S. Graham, Tara L. Fernandez, Carl L. Hansen, Ester Falconer, John R. Mascola, Bryan E. Jones, and Bryan C. Barnhart. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. *Cell Reports*, 39(7), May 2022. ISSN 2211-1247. doi: 10.1016/j.celrep.2022.110812.
18. Jinhui Dong, Seth J. Zost, Allison J. Greaney, Tyler N. Starr, Adam S. Dingens, Elaine C. Chen, Rita E. Chen, James Brett Case, Rachel E. Sutton, Pavlo Gilchuk, Jessica Rodriguez, Erica Armstrong, Christopher Gainza, Rachel S. Nargi, Elad Binshtein, Xuping Xie, Xianwen Zhang, Pei-Yong Shi, James Logue, Stuart Weston, Marisa E. McGrath, Matthew B. Frieman, Tyler Brady, Kevin M. Tuffy, Helen Bright, Yueh-Ming Loo, Patrick M. McTamney, Mark T. Esser, Robert H. Carnahan, Michael S. Diamond, Jesse D. Bloom, and James E. Crowe. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. *Nature Microbiology*, 6(10):1233–1244, Oct 2021. ISSN 2058-5276. doi: 10.1038/s41564-021-00972-2.
19. Tingting Li, Xiaojian Han, Chenjian Gu, Hangtian Guo, Huajun Zhang, Yingming Wang, Chao Hu, Kai Wang, Fengjiang Liu, Feiyang Luo, Yanan Zhang, Jie Hu, Wang Wang, Shenglong Li, Yanan Hao, Meiying Shen, Jingjing Huang, Yingyi Long, Shuyi Song, Ruixin Wu, Song Mu, Qian Chen, Fengxia Gao, Jianwei Wang, Shunhua Long, Luo Li, Yang Wu, Yan Gao, Wei Xu, Xia Cai, Di Qu, Zherui Zhang, Hongqing Zhang, Na Li, Qingzhu Gao, Guiji Zhang, Changlong He, Wei Wang, Xiaoyun Ji, Ni Tang, Zhenghong Yuan, Youhua Xie, Haitao Yang, Bo Zhang, Ailong Huang, and Aishun Jin. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. *Nature Communications*, 12(1):6304, Nov 2021. ISSN 2041-1723. doi: 10.1038/s41467-021-26539-7.
20. Hejun Liu, Meng Yuan, Deli Huang, Sandhya Bangaru, Fangzhu Zhao, Chang-Chun D. Lee, Linghang Peng, Shawn Barman, Xueyong Zhu, David Nemazee, Dennis R. Burton, Marit J. van Gils, Rogier W. Sanders, Hans-Christian Kornau, S. Momsen Reincke, Harald Prüss, Jakob Kreye, Nicholas C. Wu, Andrew B. Ward, and Ian A. Wilson. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. *Cell Host & Microbe*, 29(5):806–818.e6, May 2021. ISSN 1931-3128. doi: 10.1016/j.chom.2021.04.005.
21. Christopher O. Barnes, Claudia A. Jette, Morgan E. Abernathy, Kim-Marie A. Dam, Shannon R. Esswein, Harry B. Gristick, Andrey G. Malyutin, Naima G. Sharaf, Kathryn E. Huey-Tubman, Yu E. Lee, Davide F. Robbiani, Michel C. Nussenzweig, Anthony P. West, and Pamela J. Bjorkman. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature*, 588(7839):682–687, Dec 2020. ISSN 1476-4687. doi: 10.1038/s41586-020-2852-1.
22. Craig Fenwick, Priscilla Turelli, Dongchun Ni, Laurent Perez, Kelvin Lau, Cécile Herate, Romain Marlin, Erica Lana, Céline Pellaton, Charlène Raclot, Line Esteves-Leuenberger, Jérémy Campos, Alex Farina, Flurin Fiscalini, Nathalie Dereuddre-Bosquet, Francis Relouzat, Rana Abdelnabi, Caroline S. Foo, Johan Neyts, Pieter Leyssen, Yves Lévy, Florence Pojer, Henning Stahlberg, Roger LeGrand, Didier Trono, and Giuseppe Pantaleo. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. *Nature Microbiology*, 7(9):1376–1389, Sep 2022. ISSN 2058-5276. doi: 10.1038/s41564-022-01198-6.
23. Rungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, Helen M. Ginn, Piyada Supasa, Chang Liu, Jiandong Huo, Alexander J. Mentzer, Helen M.E. Duyvesteyn, Aiste Dijokaite-Guraliuc, Donal Skelly, Thomas G. Ritter, Ali Amini, Sagida Bibi, Sandra Adele, Sile Ann Johnson, Bede Constantinides, Hermione Webster, Nigel Temperton, Paul Klenerman, Eleanor Barnes, Susanna J. Dunachie, Derrick Crook, Andrew J. Pollard, Teresa Lambe, Philip Goulder, Neil G. Paterson, Mark A. Williams, David R. Hall, Juthathip Mongkolsapaya, Elizabeth E. Fry, Wanwisa Dejnirattisai, Jingshan Ren, David I. Stuart, and Gavin R. Screaton. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. *Cell*, 185(12):2116–2131.e18, Jun 2022. ISSN 0092-8674. doi: 10.1016/j.cell.2022.05.014.
24. G.C.P. van Zundert, J.P.G.L.M. Rodrigues, M. Trellet, C. Schmitz, P.L. Kastritis, E. Karaca, A.S.J. Melquiond, M. van Dijk, S.J. de Vries, and A.M.J.J. Bonvin. The HADDOCK2.2 web server: User-friendly integrative modeling of biomolecular complexes. *Journal of Molecular Biology*, 428(4):720–725, 2016. doi: 10.1016/j.jmb.2015.09.014.